SFDA and KAUST jointly held a workshop to discuss AI and biotechnology in medical devices. The workshop included a leadership panel with the CEO of SFDA and the President of KAUST. SFDA emphasized the Kingdom's adoption of the National Biotechnology Strategy and its focus on improving the quality of life. Why it matters: The collaboration signals Saudi Arabia's intent to be a leader in biotechnology, leveraging AI to improve healthcare and attract investment.
KAUST is joining universities worldwide to expedite licensing for COVID-19 related technologies. KAUST researchers are focusing on developing rapid diagnostic platforms, genomic analyses, and tools to track the virus's spread, collaborating with Saudi healthcare stakeholders. By signing the AUTM COVID-19 Licensing Guidelines and adopting the COVID-19 Technology Development Framework, KAUST will offer royalty-free, time-limited, non-exclusive licenses during and after the pandemic. Why it matters: This initiative facilitates quicker development and broader access to essential technologies for combating COVID-19 in Saudi Arabia and the Middle East.
KAUST and the Marine Technology Society (MTS) have formed the MTS Red Sea Section, the first MTS Section in the Middle East. KAUST hosted the MATE ROV Red Sea Regional competition and RobotoKAUST, sponsored by the MTS Red Sea Section. Saudi Arabia is investing heavily in the Blue Economy, and KAUST is positioning itself at the forefront of marine science and technology for the Red Sea. Why it matters: This partnership and KAUST's activities will foster marine technology development and talent growth in the region, aligning with Saudi Arabia's Blue Economy initiatives.
KAUST is supporting Saudi Arabia's healthcare modernization by translating laboratory research into smart, digital, and precise solutions. One example is the Social and Personal Adaptive Response Kit (SPARK), an AI-driven technology integrating behavioral analysis, wearable multi-sensor systems, and human body communication to support children with autism. KAUST researchers have also developed a fully printed wireless electrocardiogram system and a smart bandage for various applications. Why it matters: These innovations align with Saudi Vision 2030 and have the potential to improve healthcare outcomes in Saudi Arabia and globally through personalized, remote care.
KAUST and KFSHRC have developed NanoRanger, a new gene sequencing system for identifying mutations causing genetic diseases. NanoRanger offers a faster and simpler process to detect DNA abnormalities at base resolution, building on existing long-read sequencing technologies. The system is designed to be cheaper and faster, targeting diseases prevalent in Saudi Arabia due to consanguinity. Why it matters: The technology has the potential to improve diagnosis and treatment of Mendelian diseases, which are especially prevalent in the Arab world.
KAUST and Saudi healthtech company amplifAI health have signed an MoU to develop a new disease detection system. The system will combine amplifAI's AI technology with KAUST's HyplexTM hyperspectral imaging, initially for diabetic foot complications. Clinical trials are planned, with aims to reduce amputations and save Saudi Arabia over 2 billion Riyals annually. Why it matters: This partnership showcases the potential of combining Saudi AI and advanced imaging technologies to address pressing healthcare challenges in the region, particularly diabetes.